Emraclidine

SystImmune will present updated safety and efficacy data for izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjugate, in locally advanced or metastatic breast cancer at ESMO Breast 2025 on May 16.

Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride) did not achieve statistical significance as an adjunctive therapy for schizophrenia in the Phase 3 ARISE trial, showing only a 2.0-point reduction in PANSS scores compared to placebo.

BasgenBio secures a 1 billion won ($684,090) deal with Novartis to implement AI-driven digital twin technology for predicting side effects in breast cancer patients.

DelveInsight's latest pipeline report reveals over 55 pharmaceutical companies actively developing 60+ innovative drug candidates for schizophrenia treatment, indicating significant industry investment in addressing this serious mental illness.

AbbVie faces a $3.5 billion impairment charge following emraclidine's Phase 2 trial failures, but maintains potential for its development as an adjunctive treatment.